Recombinant human PTH 1-34 (Forteo): an anabolic drug for osteoporosis.
Forteo (teriparatide of rDNA origin), a genetically engineered fragment of parathyroid hormone, is the first of a new class of drugs to treat osteoporosis. The drug's anabolic action increases bone turnover, stimulating osteoblasts to a greater extent than osteoclasts, and reducing both vertebral and nonvertebral fractures. However, a number of issues about its use remain unanswered.
Deal
Chad
C
Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic Foundation, OH 44195, USA.
Gideon
James
J
D000595:Amino Acid Sequence; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology; D002986:Clinical Trials as Topic; D000075202:Contraindications; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D008969:Molecular Sequence Data; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use*; D019379:Teriparatide / Q000191:economics / Q000627:therapeutic use*
D011994:Recombinant Proteins; D019379:Teriparatide